Arkolith/Insider Trading/VRCA/Form 4

Manning Paul B

Director, 10% OwnerVerrica Pharmaceuticals Inc. (VRCA) · full profile →Form 4 · filed Nov 26, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
7
3 non-derivative · 4 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Nov 26, 2024Gift(G)450K—$025.8M
Nov 22, 2024Buy(P)18.4M——26.3M
Nov 22, 2024Buy(P)4.5M——6.0M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Nov 22, 2024Buy(P)9.2M——9.2M
Nov 22, 2024Buy(P)2.2M——2.2M
Nov 22, 2024Buy(P)2.2M——2.2M
Nov 22, 2024Buy(P)9.2M——9.2M

Transaction Codes

G
Gift
P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001415889-24-027709) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML